C4X Discovery Holdings plc announces that it has received a milestone payment of 3 million from Sanofi under the IL-17A Inhibitor programme license agreement entered into in April 2021. Under the terms of the deal, C4XD is entitled to up to a total of 414 million in upfront, pre-clinical, development, regulatory and commercialisation milestone payments plus royalties on future net sales.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12 GBX | +27.32% | -.--% | +33.33% |
25/04 | Norcros sells Johnson Tiles UK; Trifast trading well | AN |
25/04 | C4X Discovery Set for Friday Delisting from London Bourse's AIM | MT |
1st Jan change | Capi. | |
---|---|---|
+33.33% | 37.99M | |
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- C4XD Stock
- News C4X Discovery Holdings plc
- C4X Discovery Holdings plcReceives Sanofi Milestone Payment